Get started
Author

Therese Blidberg

Institution: BioInvent (Sweden)
Observed institution: BioInvent (Sweden)
ORCID: 0009-0004-1278-0830
Observed ORCID: 0009-0004-1278-0830
OpenAlex ID: A5070337814
Abstract 936: Targeting TNFR2 for cancer immunotherapy: Ligand blocking depletors versus receptor agonists
2020 · Linda Mårtensson, Kirstie Cleary, et al. · Cancer Research · 10
725 Pre-clinical development of TNFR2 ligand-blocking BI-1808 for cancer immunotherapy
2020 · Linda Mårtensson, Mathilda Kovacek, et al. · Journal for ImmunoTherapy of Cancer · 9
Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al. · Cancer Research · 3
1368 Preclinical development of an agonistic anti-TNFR2 antibody (BI-1910) for cancer immunotherapy
2023 · Linda Martensson, Petra Holmkvist, et al. · Journal for ImmunoTherapy of Cancer · 3
PDF
Abstract 4156: BI-1808 - a first in class ligand-blocking αTNFR2 antibody for cancer immunotherapy
2022 · Linda Mårtensson, Kirsty Cleary, et al. · Cancer Research · 3
Supplementary Fig 1 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Fig 5 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Fig 4 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Table 1 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Data from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Fig 3 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Fig 10 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Fig 8 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Anti-TNFR2 antibody BI-1808 induces tumor regression and antitumor T cell immunity through T reg and myeloid cell modulation in patients with solid tumors
2026 · Ingrid Teige, Kristoffer S. Rohrberg, et al. · Clinical Cancer Research
Supplementary Fig 9 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Fig 7 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Fig 2 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Fig 6 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Materials and Methods from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Abstract 3423: A novel FcγRIIB-blocking antibody to enhance FcγR-dependent antitumor immunity with anti-HER2 therapy
2022 · Linda Mårtensson, Robert Oldham, et al. · Cancer Research
Abstract 1642: A novel FcγRIIB-blocking antibody to enhance FcγR-dependent antitumor immunity
2021 · Linda Mårtensson, Robert Oldham, et al. · Cancer Research
Establishment of an In Vivo Mouse Model to Study and Overcome Infusion Related Reactions Associated with Fcgriib Antibody Administration
2020 · Ingrid Karlsson, Linda Mårtensson, et al. · Blood
Works count: 22
Citation count: 28
H-index: 3
I10-index: 1
Year
Topic
Type